Stock Price Quote

GRANULES INDIA LTD.

NSE : GRANULESBSE : 532482ISIN CODE : INE101D01020Industry : Pharmaceuticals & DrugsHouse : Private
BSE414.30-0.4 (-0.1 %)
PREV CLOSE ( ) 414.70
OPEN PRICE ( ) 418.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 29241
TODAY'S LOW / HIGH ( )413.05 419.65
52 WK LOW / HIGH ( )272 480.5
NSE414.500.15 (+0.04 %)
PREV CLOSE( ) 414.35
OPEN PRICE ( ) 417.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 414.50 (633)
VOLUME 294332
TODAY'S LOW / HIGH( ) 413.55 419.50
52 WK LOW / HIGH ( )272.35 480.45
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 18-03 1991
Management Info
Krishna Prasad Chigurupati - Chairman Krishna Prasad Chigurupati - Managing Director
Registered Office

Address Second Floor ,Block No 3,My Home Hub, Madhapur,
Hyderabad,
Telangana-500081

Phone 040-69043500

Email mail@granulesindia.com / investorrelations@granulesindia.com

Website www.granulesindia.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX

NEWS

13Apr Granules India gets zero observations
Granules India’s Unit V facility located at Anakapally, Visakhapatnam, A..
12Apr US FDA Audit For Granules India'S Uni
US FDA audit for Granules India''s Unit V facility results in Zero 483s
03Apr Granules India’s arm gets VAI classifi
Granules India’s wholly-owned foreign subsidiary -- Granules Pharmaceuti..
03Apr Granules India informs about update on
With respect to communication dated December 16, 2023, regarding the US..
28Mar Granules India informs about closure o
Pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and G..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit1427.054987.85
Gross Profit 1916.12 6639.4
Operating Profit 2475.58481.71
Net Sales 9844.8539312

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Fredun Pharma (BSE)
peergroup  827.60 (8.15%)
M.Cap ( in Cr)390.76
Mankind Pharma (BSE)
peergroup  2393.90 (2.40%)
M.Cap ( in Cr)95896.87
Torrent Pharma (BSE)
peergroup  2636.30 (1.76%)
M.Cap ( in Cr)89224.37
Ajanta Pharma (BSE)
peergroup  2135.80 (2.17%)
M.Cap ( in Cr)26893.07
Strides Pharma Scien (BSE)
peergroup  890.20 (5.24%)
M.Cap ( in Cr)8180.91

Shareholding Pattern

MUTUAL FUNDS/UTI 7.09%
PROMOTERS 41.96%
FI/BANKS/INSURANCE 3.59%
NON-INSTITUTION 27.77%
GOVERNMENT 0%
FII 0%

About Granules India Ltd.

Granules India Ltd. was incorporated in the year 1991. Its today's share price is 414.3. Its current market capitalisation stands at Rs 10041.34 Cr. In the latest quarter, company has reported Gross Sales of Rs. 39312 Cr and Total Income of Rs.39440.84 Cr. The company's management includes Kapil Kumar Mehan, Sucharita Rao Palepu, Saumen Chakraborty, Arun Sawhney, KB Sankar Rao, Harsha Chigurupati, Uma Devi Chigurupati, Kandiraju Venkata Sitaram Rao, Krishna Prasad Chigurupati, Krishna Prasad Chigurupati, Chaitanya Tummala.

It is listed on the BSE with a BSE Code of 532482 , NSE with an NSE Symbol of GRANULES and ISIN of INE101D01020. It's Registered office is at Second Floor ,Block No 3,My Home Hub, MadhapurHyderabad-500081, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Associates LLP, Kumar & Giri, SR Batliboi & Associates LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.